These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31951173)

  • 1. Nanotherapies for the Treatment of Age-Related Macular Degeneration (AMD) Disease: Recent Advancements and Challenges.
    Rapalli VK; Gorantla S; Waghule T; Mahmood A; Singh PP; Dubey SK; Saha RN; Singhvi G
    Recent Pat Drug Deliv Formul; 2019; 13(4):283-290. PubMed ID: 31951173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention and treatment of age-related macular degeneration: an update for pharmacists.
    Marshall LL; Roach JM
    Consult Pharm; 2013 Nov; 28(11):723-37. PubMed ID: 24217192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.
    Becerra EM; Morescalchi F; Gandolfo F; Danzi P; Nascimbeni G; Arcidiacono B; Semeraro F
    Curr Drug Targets; 2011 Feb; 12(2):149-72. PubMed ID: 20887246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration.
    Feng L; Hu JH; Chen J; Xie X
    J Zhejiang Univ Sci B; 2018 Apr.; 19(4):327-332. PubMed ID: 29616508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.
    Eyetech Study Group
    Retina; 2002 Apr; 22(2):143-52. PubMed ID: 11927845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuning surface functionalities of sub-10 nm-sized nanocarriers to target outer retina in designing drug delivery agents for intravitreal administration.
    You S; Kim H; Jung HY; Kim B; Lee EJ; Kim JW; Kim Y
    Biomaterials; 2020 Oct; 255():120188. PubMed ID: 32652402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical Drug Delivery to the Posterior Segment of the Eye: Addressing the Challenge of Preclinical to Clinical Translation.
    Rodrigues GA; Lutz D; Shen J; Yuan X; Shen H; Cunningham J; Rivers HM
    Pharm Res; 2018 Oct; 35(12):245. PubMed ID: 30374744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retinal function determined by flicker ERGs before and soon after intravitreal injection of anti-VEGF agents.
    Terauchi G; Shinoda K; Sakai H; Kawashima M; Matsumoto CS; Mizota A; Miyake Y
    BMC Ophthalmol; 2019 Jun; 19(1):129. PubMed ID: 31208350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration.
    Lee SJ; Koh HJ
    Ophthalmology; 2011 Jan; 118(1):101-10. PubMed ID: 20678805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.
    Waisbourd M; Loewenstein A; Goldstein M; Leibovitch I
    Drugs Aging; 2007; 24(8):643-62. PubMed ID: 17702534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal injection of aflibercept, an anti-VEGF antagonist, down-regulates plasma von Willebrand factor in patients with age-related macular degeneration.
    Yamashita M; Matsumoto M; Hayakawa M; Sakai K; Fujimura Y; Ogata N
    Sci Rep; 2018 Jan; 8(1):1491. PubMed ID: 29367644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors.
    Mehta H; Tufail A; Daien V; Lee AY; Nguyen V; Ozturk M; Barthelmes D; Gillies MC
    Prog Retin Eye Res; 2018 Jul; 65():127-146. PubMed ID: 29305324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-responsiveness and tachyphylaxis to anti-vascular endothelial growth factor treatment in naive patients with exudative age-related macular degeneration.
    Zuber-Laskawiec K; Kubicka-Trzaska A; Karska-Basta I; Pociej-Marciak W; Romanowska-Dixon B
    J Physiol Pharmacol; 2019 Oct; 70(5):. PubMed ID: 32009630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review.
    Yang S; Zhao J; Sun X
    Drug Des Devel Ther; 2016; 10():1857-67. PubMed ID: 27330279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration.
    Semeraro F; Morescalchi F; Parmeggiani F; Arcidiacono B; Costagliola C
    Curr Vasc Pharmacol; 2011 Sep; 9(5):629-46. PubMed ID: 21470108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical Dorzolamide-Timolol With Intravitreous Anti-Vascular Endothelial Growth Factor for Neovascular Age-Related Macular Degeneration.
    Sridhar J; Hsu J; Shahlaee A; Garg SJ; Spirn MJ; Fineman MS; Vander J
    JAMA Ophthalmol; 2016 Apr; 134(4):437-43. PubMed ID: 26914218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-VEGF agents for age-related macular degeneration.
    Ozkiris A
    Expert Opin Ther Pat; 2010 Jan; 20(1):103-18. PubMed ID: 20021287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profile of conbercept in the treatment of neovascular age-related macular degeneration.
    Lu X; Sun X
    Drug Des Devel Ther; 2015; 9():2311-20. PubMed ID: 25960634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
    Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ
    Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.